on Nanohale AG (isin : DE000A1EWVY8)
Formycon AG's FYB202 Biosimilar Approved for EU and US Markets
First Berlin Equity Research GmbH has released a research update on Formycon AG, maintaining a "Buy" recommendation and raising the target price from €80 to €82. Analyst Simon Scholes cited the EU and US approvals of the Stelara biosimilar FYB202 as key factors.
Formycon, along with their commercialization partner Fresenius Kabi, announced the regulatory decisions on 27 September, allowing for market entry in the US by 22 February 2025. This new timeline places them joint third among seven companies aiming to launch biosimilars between January and May next year.
The earlier market entry boosts FYB202’s market share prospects, prompting First Berlin Equity Research to revise its forecasts upward. This strategic adjustment underscores the optimism around Formycon AG's upcoming commercial activities.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news